Phio Pharmaceuticals' PH-762 Skin Cancer Study Charges to Fourth Dose

2025-04-09 09:00:55 ET

DENVER, Colo., Apr 09, 2025 ( 247marketnews.com )- Phio Pharmaceuticals (NASDAQ:PHIO) reports positive data from its INTASYL PH-762 skin cancer trial. Announced today, the Safety Monitoring Committee (SMC) gave a green light to crank PH-762’s Phase 1b trial (NCT 06014086) to its fourth dose cohort, signaling this siRNA champ’s safety profile is rock-solid—and tariffs? Down here, they’re just background noise.

Mary Spellman, MD, Phio’s acting Chief Medical Officer, said, “We are impressed with the continuing safety profile of PH-762 having now progressed through the first 3 escalating doses.”

PH-762, Phio’s lead weapon against cutaneous cancers, aced its third cohort—three patients with squamous cell carcinoma took the intratumoral shots, with no serious adverse events or dose-limiting toxicities. Pathology results are pending, but earlier cohorts dazzle: in cohort two (four patients), two nailed a complete response (100% tumor clearance) by Day 36, one hit a 90% partial response, and the fourth held steady. Cohort one’s three patients all stayed stable too—no tariff woes here, just U.S.-driven biotech grit slashing cancer in an estimated $10 billion skin cancer market.

The post Phio Pharmaceuticals’ PH-762 Skin Cancer Study Charges to Fourth Dose appeared first on 24/7 MarketNews .

For further details see: